Relief Therapeutics Holding AG (via Public) / Relief Reports that its U S Collaboration Partner has Announced a Positive Safety Report for ZYESAMI(TM) (aviptadil) in NIH Sponsored ACTIV-3 Study in Patients with Life-Threatening COVID-19 publicnow.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from publicnow.com Daily Mail and Mail on Sunday newspapers.
19.08.2021 - EQS Group-News: RELIEF THERAPEUTICS Holdings AG / Key word(s): Study Relief Reports that its U.S. Collaboration Partner has Announced a Positive Safety Report for ZYESAMI(TM) (aviptadil) in NIH Sponsored ACTIV-3 Study in Patients with . Seite 1
EQS Group-News: RELIEF THERAPEUTICS Holdings AG / Key word(s): Study19.08.2021 / 07:00 Relief Reports that its U.S. Collaboration Partner has Announced a Positive Safety Report for ZYESAMI(TM) (aviptadil) in NIH Sponsored ACTIV-3 Critical Care Study in Patients with Life-Threatening COVID-19Geneva, Switzerland.
EQS Group-News: RELIEF THERAPEUTICS Holdings AG / Key word(s): Study Relief Reports that its U.S. Collaboration Partner has Announced a Positive Safety Report for ZYESAMI(TM) (aviptadil) in NIH Sponsored ACTIV-3 Study in Patients with Life-Threatening COVID-19 19.08.2021 / 07:00 Relief Reports.